Review

Published on 30 Apr 2024

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

in Pharmacology of Anti-Cancer Drugs

Marjorie A. Shapiro

Frontiers in Oncology

doi 10.3389/fonc.2024.1379738

4,319 views
3 citations

Original Research

Published on 25 Apr 2024

Body composition and inflammation variables as the potential prognostic factors in epithelial ovarian cancer treated with Olaparib

in Pharmacology of Anti-Cancer Drugs

Xingzi Guo
Jie Tang
Haifeng He
Lian Jian
Ouyang Qiang
Yongzhi Xie

Frontiers in Oncology

doi 10.3389/fonc.2024.1359635

1,125 views

Review

Published on 23 Apr 2024

Cancer related cognitive impairment: a downside of cancer treatment

in Pharmacology of Anti-Cancer Drugs

Kimberly Demos-Davies
Jessica Lawrence
Davis Seelig

Frontiers in Oncology

doi 10.3389/fonc.2024.1387251

2,265 views
2 citations

Original Research

Published on 16 Apr 2024

Role of proteoglycan synthesis genes in osteosarcoma stem cells

in Pharmacology of Anti-Cancer Drugs

Ryoma Osumi
Kengo Sugihara
Makoto Yoshimoto
Kazuya Tokumura
Yuki Tanaka
Eiichi Hinoi

Frontiers in Oncology

doi 10.3389/fonc.2024.1325794

1,411 views
1 citation

Editorial

Published on 05 Apr 2024

Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine

in Pharmacology of Anti-Cancer Drugs

Aimin Jiang
Wangxiao He
Yu Yao

Frontiers in Oncology

doi 10.3389/fonc.2024.1406244

782 views
1 citation

Editorial

Published on 04 Apr 2024

Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

in Pharmacology of Anti-Cancer Drugs

Marcel Henrique Marcondes Sari
Luana Mota Ferreira

Frontiers in Oncology

doi 10.3389/fonc.2024.1403778

488 views

Review

Published on 25 Mar 2024

Research progress on the antitumor effects of harmine

in Pharmacology of Anti-Cancer Drugs

Yonghua Hu
Xiaoli Yu
Lei Yang
Gaimei Xue
Qinglin Wei
Zhijian Han
Hao Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1382142

2,184 views
1 citation

Original Research

Published on 21 Mar 2024

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

in Pharmacology of Anti-Cancer Drugs

Anna Spreafico
Eva Muñoz Couselo
Anja Irmisch
Juliana Bessa
George Au-Yeung
Oliver Bechter
Inge Marie Svane
Miguel F. Sanmamed
Valentina Gambardella
Meredith McKean

Frontiers in Oncology

doi 10.3389/fonc.2024.1346502

4,117 views

Original Research

Published on 20 Mar 2024

Pyroptosis-related gene signature for predicting gastric cancer prognosis

in Pharmacology of Anti-Cancer Drugs

Salem Saeed Saad Khamis
Jianhua Lu
Yongdong Yi
Shangrui Rao
Weijian Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1336734

1,414 views
1 citation

Case Report

Published on 07 Mar 2024

Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Valérian Rivet
Vincent Sibaud
Jérémie Dion
Thibaut Volosov
Mélanie Biteau
Andréa Pastissier
Karen Delavigne
Pierre Cougoul
Odile Rauzy
Thibault Comont

Frontiers in Oncology

doi 10.3389/fonc.2024.1353896

1,425 views
1 citation

Original Research

Published on 07 Mar 2024

Photodynamic therapy with paclitaxel-encapsulated indocyanine green-modified liposomes for breast cancer

in Pharmacology of Anti-Cancer Drugs

Mariko Ishizuka
Masaki Kaibori
Fusao Sumiyama
Yoshiharu Okamoto
Akiko Suganami
Yutaka Tamura
Kengo Yoshii
Tomoharu Sugie
Mitsugu Sekimoto

Frontiers in Oncology

doi 10.3389/fonc.2024.1365305

2,125 views

Original Research

Published on 26 Feb 2024

Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model

in Pharmacology of Anti-Cancer Drugs

Anahita Piranfar
Mohammad Souri
Arman Rahmim
Madjid Soltani

Frontiers in Oncology

doi 10.3389/fonc.2024.1320371

1,550 views
7 citations

Original Research

Published on 26 Feb 2024

The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments

in Pharmacology of Anti-Cancer Drugs

Denise Robinson
Hugh Leonard
Giacomo Giulio Baldi
William D. Tap
Robin L. Jones
Silvia Stacchiotti
Pan Pantziarka

Frontiers in Oncology

doi 10.3389/fonc.2024.1367237

1,974 views
1 citation

Original Research

Published on 22 Feb 2024

Identification and validation of a gap junction protein related signature for predicting the prognosis of renal clear cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Yongsheng Huang
Wenyi Guo
Yuan Zeng
Xinrong Wang
Bohao Fan
Ying Zhang
Lei Yan
Gangli Gu
Zhao Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1354049

2,217 views

Case Report

Published on 22 Feb 2024

Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature

in Pharmacology of Anti-Cancer Drugs

Ahmed Abdalhadi
Nabil E. Omar
Samah Kohla
Hassan Aakel
Yeslem Ekeibed
Reyad Mohsen

Frontiers in Oncology

doi 10.3389/fonc.2024.1275275

1,771 views
2 citations

Original Research

Published on 22 Feb 2024

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

in Pharmacology of Anti-Cancer Drugs

Ningning Yan
Sanxing Guo
Siyuan Huang
Huixian Zhang
Xingya Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1331128

2,235 views

Navigation group

Articles

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

Body composition and inflammation variables as the potential prognostic factors in epithelial ovarian cancer treated with Olaparib

Cancer related cognitive impairment: a downside of cancer treatment

Role of proteoglycan synthesis genes in osteosarcoma stem cells

Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine

Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

Research progress on the antitumor effects of harmine

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Pyroptosis-related gene signature for predicting gastric cancer prognosis

Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review

Photodynamic therapy with paclitaxel-encapsulated indocyanine green-modified liposomes for breast cancer

Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model

The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments

Identification and validation of a gap junction protein related signature for predicting the prognosis of renal clear cell carcinoma

Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience